Discovery of a potent and subtype-selective TYK2 degrader based on an allosteric TYK2 inhibitor

被引:7
|
作者
Kato, Jun-ya [1 ]
Korenaga, Shigeru [2 ]
Iwakura, Masaru [1 ]
机构
[1] ASKA Pharmaceut Co Ltd, Synthet Res Dept, 26-1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 2518555, Japan
[2] ASKA Pharmaceut Co Ltd, Drug Discovery Dept, 26-1 Muraoka Higashi 2 Chome, Fujisawa, Kanagawa 2518555, Japan
关键词
Tyrosine kinase 2 (TYK2); Janus kinase (JAK); Proteolysis-targeting chimera (PROTAC); VonHippel-Lindau (VHL); Degrader; Allosteric TYK2 inhibitor; PROTEIN-DEGRADATION; PROTACS; MOLECULES; STRATEGY;
D O I
10.1016/j.bmcl.2022.129083
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
TYK2, a member of the JAK family of proximal membrane-bound tyrosine kinases, has emerged as an attractive target for the treatment of autoimmune diseases. Herein, we report the discovery of first-in-class potent and subtype-selective TYK2 degraders. By conjugating a TYK2 ligand from a known allosteric TYK2 inhibitor with a VHL ligand as the E3 ligase ligand via alkyl linkers of various lengths, we rapidly identified TYK2 degrader 5 with moderate TYK2 degradation activity. Degrader 5 induced TYK2 degradation without affecting the protein level of subtype kinases (JAK1, JAK2, and JAK3) in Jurkat cellular assays. Furthermore, modifying the TYK2 ligand moiety of degrader 5 yielded the more potent TYK2 degrader 37 with retained selectivity for JAKs. Our subtype -selective TYK2 degraders represent valuable chemical probes for investigating the biology of TYK2 degradation.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Discovery of a Potent and Subtype-Selective Tyk2 Degrader Based on an Allosteric Tyk2 Inhibitor
    Kato, Jun-Ya
    Korenaga, Shigeru
    Iwakura, Masaru
    SSRN, 2022,
  • [2] Targeting the Tyrosine Kinase 2 (TYK2) Pseudokinase Domain: Discovery of the Selective TYK2 Inhibitor ABBV-712
    Breinlinger, Eric
    Van Epps, Stacy
    Friedman, Michael
    Argiriadi, Maria
    Chien, Ellen
    Chhor, Gekleng
    Cowart, Marlon
    Dunstan, Theresa
    Graff, Candace
    Hardee, David
    Herold, J. Martin
    Little, Andrew
    Mccarthy, Richard
    Parmentier, Julie
    Perham, Matthew
    Qiu, Wei
    Schrimpf, Michael
    Vargo, Thomas
    Webster, Matthew P.
    Wu, Fei
    Bennett, Dawn
    Edmunds, Jeremy
    JOURNAL OF MEDICINAL CHEMISTRY, 2023, 66 (20) : 14335 - 14356
  • [3] Discovery of BMS-986202: A Clinical Tyk2 Inhibitor that Binds to Tyk2 JH2
    Liu, Chunjian
    Lin, James
    Langevine, Charles
    Smith, Daniel
    Li, Jianqing
    Tokarski, John S.
    Khan, Javed
    Ruzanov, Max
    Strnad, Joann
    Zupa-Fernandez, Adriana
    Cheng, Lihong
    Gillooly, Kathleen M.
    Shuster, David
    Zhang, Yifan
    Thankappan, Anil
    McIntyre, Kim W.
    Chaudhry, Charu
    Elzinga, Paul A.
    Chiney, Manoj
    Chimalakonda, Anjaneya
    Lombardo, Louis J.
    Macor, John E.
    Carter, Percy H.
    Burke, James R.
    Weinstein, David S.
    JOURNAL OF MEDICINAL CHEMISTRY, 2021, 64 (01) : 677 - 694
  • [4] Identification of imidazo[1,2-b] pyridazine TYK2 pseudokinase ligands as potent and selective allosteric inhibitors of TYK2 signalling
    Moslin, R.
    Gardner, D.
    Santella, J.
    Zhang, Y.
    Duncia, J. V.
    Liu, C.
    Lin, J.
    Tokarski, J. S.
    Strnad, J.
    Pedicord, D.
    Chen, J.
    Blat, Y.
    Zupa-Fernandez, A.
    Cheng, L.
    Sun, H.
    Chaudhry, C.
    Huang, C.
    D'Arienzo, C.
    Sack, J. S.
    Muckelbauer, J. K.
    Chang, C.
    Tredup, J.
    Xie, D.
    Aranibar, N.
    Burke, J. R.
    Carter, P. H.
    Weinstein, D. S.
    MEDCHEMCOMM, 2017, 8 (04) : 700 - 712
  • [5] Discovery of a pseudokinase domain ligand as an allosteric inhibitor of TYK2 for the treatment of autoimmune diseases
    Weinstein, David
    Wrobleski, Steve
    Moslin, Ryan
    Lin, Shuqun
    Zhang, Yanlei
    Spergel, Steven
    Mertzman, Michael
    Tokarski, John
    Sun, Huadong
    Chiney, Manoj
    Elzinga, Paul
    Aranibar, Nelly
    Chimalakonda, Anjaneya
    Strnad, Joann
    Zupa-Fernandez, Adriana
    Cheng, Lihong
    Gillooly, Kathleen
    Mcintyre, Kim
    Carter, Percy
    Lombardo, Louis
    Burke, James
    Macor, John
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2016, 252
  • [6] Central TYK2 Inhibition Identifies TYK2 as a Key Neuroimmune Modulator
    Molitor, Tyler
    Hayashi, Genki
    Lin, Mei-Yao
    Dunn, Carissa
    Peterson, Nathan
    Poston, Robert
    Kurnellas, Michael
    Traver, David
    Patel, Seona
    Akgungor, Zeynep
    Leonardi, Virginia
    Lewis, Colizel
    Segales, Joshua
    Wood, Steve
    Rassoulpour, Arash
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 611 - 611
  • [7] Design of a potent and selective dual JAK1/TYK2 inhibitor
    Mammoliti, Oscar
    Menet, Christel
    Cottereaux, Celine
    Blanc, Javier
    De Blieck, Ann
    Coti, Ghjuvanni
    Geney, Raphael
    Oste, Line
    Ostyn, Koen
    Palisse, Adeline
    Quinton, Evelyne
    Schmitt, Benoit
    Borgonovi, Monica
    Parent, Isabelle
    Jagerschmidt, Catherine
    De Vos, Steve
    Vayssiere, Beatrice
    Lopez-Ramos, Miriam
    Shoji, Kenji
    Brys, Reginald
    Amantini, David
    Galien, Rene
    Joannesse, Caroline
    BIOORGANIC & MEDICINAL CHEMISTRY, 2024, 114
  • [8] Targeting TYK2 for Fighting Diseases: Recent Advance of TYK2 Inhibitors
    Du, Si-Shi
    Fang, Yu-Qing
    Zhang, Wen
    Rao, Guo-Wu
    CURRENT MEDICINAL CHEMISTRY, 2024, 31 (20) : 2900 - 2920
  • [9] Selective JAK1 inhibitor and selective Tyk2 inhibitor patents
    Norman, Peter
    EXPERT OPINION ON THERAPEUTIC PATENTS, 2012, 22 (10) : 1233 - 1249
  • [10] TYK2 in Tumor Immunosurveillance
    Karjalainen, Anzhelika
    Shoebridge, Stephen
    Krunic, Milica
    Simonovic, Natalija
    Tebb, Graham
    Macho-Maschler, Sabine
    Strobl, Birgit
    Mueller, Mathias
    CANCERS, 2020, 12 (01)